The present invention relates to the use of an angular psoralen, trimethylangelicin (4,6,4 '-trime thy langelicin - TMA), a molecule able to correct the intracellular localisation of the membrane protein called CFTR (Cystic Fibrosis Transmembrane conductance Regulator) carrying the F508del CFTR mutation, which is altered in a sub-group of patients suffering from cystic fibrosis. Said molecule is proposed for the preparation of a medicament for the treatment of cystic fibrosis (CF) in the sub-group of patients characterised by the F508del mutation of the CFTR gene.
TRIMETHYLANGELICIN AS CFTR CORRECTOR IN BRONCHIAL EPITHELIAL CELLS
CABRINI, GIULIO;
2012-01-01
Abstract
The present invention relates to the use of an angular psoralen, trimethylangelicin (4,6,4 '-trime thy langelicin - TMA), a molecule able to correct the intracellular localisation of the membrane protein called CFTR (Cystic Fibrosis Transmembrane conductance Regulator) carrying the F508del CFTR mutation, which is altered in a sub-group of patients suffering from cystic fibrosis. Said molecule is proposed for the preparation of a medicament for the treatment of cystic fibrosis (CF) in the sub-group of patients characterised by the F508del mutation of the CFTR gene.
File in questo prodotto:
Non ci sono file associati a questo prodotto.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
